{"url_path":"/sec/sndx/8-k/2026-06-04/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-04","source_url":"https://www.sec.gov/Archives/edgar/data/1395937/0001193125-26-256458-index.html","accession_number":"0001193125-26-256458","cik":"0001395937","ticker":"SNDX","issuer_name":"Syndax Pharmaceuticals Inc","edgar_url":"https://www.sec.gov/Archives/edgar/data/1395937/0001193125-26-256458-index.html","primary_entity_key":"0001395937","primary_entity_name":"Syndax Pharmaceuticals Inc"},"word_count":100,"has_tables":true,"body_markdown":"Item 9.01\n\nFinancial Statements and Exhibits.\n\n(d) Exhibits\n\n \n\nExhibit\nNo.\n  \n\nDescription\n\n10.1\n  \n[Form of Subscription Agreement](d65010dex101.htm)\n\n99.1\n  \n[Press release entitled “Syndax Announces Private Placement of $250.0 Million of Convertible Senior Notes,” dated June 4, 2026](d65010dex991.htm)\n\n104\n  \nCover Page Interactive Data File (embedded within the Inline XBRL document)\n\n \n\n \n\n5\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \nSyndax Pharmaceuticals, Inc.\n\nDated: June 4, 2026\n \n\n \n\n \nBy:\n \n\n/s/ Michael A. Metzger\n\n \n\n \n\n \nMichael A. Metzger\n\n \n\n \n\n \nChief Executive Officer\n\n \n\n6"}